Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305383 · ClinicalTrials.gov registry record · Phase 2
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
A Phase 2 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00305383 is a Phase 2 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 100 participants.
The verdict
NCT00305383, a Phase 2 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that receives 4 weeks of viramidine monotherapy prior to the start of peginterferon alfa-2b/viramidine combination therapy.
Interventions
- DRUG Peginterferon alfa-2b
- DRUG Viramidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305383
The ClinicalTrials.gov registry entry for NCT00305383 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Peginterferon alfa-2b is the first listed.
NCT00305383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305383 about?
NCT00305383 is a clinical study titled "Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C". The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that receives 4 weeks of viramidine monotherapy prior to the start of peginter...
What is the current status of trial NCT00305383?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2005-11. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00305383?
The interventions under investigation include: Peginterferon alfa-2b (DRUG), Viramidine (DRUG).
Who is sponsoring clinical trial NCT00305383?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.